Approval · Notice of Compliance 36500 · 2025
AG-VALACYCLOVIR: Notice of Compliance 36500
Issued December 9, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36500
- Date
- December 9, 2025
- Company
- Angita Pharma Inc.Boucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Update to labelling (to match Licensor). Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AG-VALACYCLOVIR | Not yet assigned | — |
| AG-VALACYCLOVIR | 02563622 | Approved |
Medicinal ingredients
- VALACYCLOVIR HYDROCHLORIDE 500 MG per TAB
- VALACYCLOVIR HYDROCHLORIDE 1,000 MG per TAB